LAUSR

Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: AstraZeneca; Research grant/Funding (self): Boehringer Ingelheim. A.B. El-Khoueiry: Honoraria (self), Advisory/Consultancy: CytomX Therapeutics; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Eisai; Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Merck; Honoraria (self), Advisory/Consultancy: Exelixis; Honoraria (self), Advisory/Consultancy: Pieris Pharmaceuticals; Honoraria (self), Advisory/Consultancy: Agenus; Honoraria (self), Advisory/Consultancy: Gilead Sciences; Honoraria (self), Advisory/Consultancy: AstraZeneca/MedImmune; Honoraria (self): Roche/Genentech; Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): Astex Pharmaceuticals. A. Vogel: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Novartis; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy, Travel, accommodations, expenses: Roche; Honoraria (self), Advisory/Consultancy: Amgen; Advisory/Consultancy, Travel, accommodations, expenses: Bayer; Advisory/Consultancy: Baxalta; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Eisai; Advisory/Consultancy: BTG; Honoraria (self), Advisory/Consultancy, Travel, accommodations, expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Pierre Fabre; Honoraria (self): Sanofi; Honoraria (self): Delcath Systems; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): MSD; Honoraria (self): Janssen. D.C. Madoff: Shareholder/Stockholder/Stock options: RenovoRX; Advisory/Consultancy, Travel, Accommodations, Expenses: Boston Scientific; Advisory/Consultancy, Travel, Accommodations, Expenses: Guerbet; Advisory/Consultancy, Travel, Accommodations, Expenses: Quantum Surgical. R.S. Finn: Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy, Research grant/Funding (institution): Genentech/Roche; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Exelixis; Advisory/Consultancy: C Stone Pharma. S. Ogasawara: Honoraria (self), Advisory/ Consultancy, Research grant/Funding (self): Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Eisai; Advisory/Consultancy: Merck; Advisory/Consultancy: Chugai Pharma; Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Lilly. Z. Ren: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Merck. K. Mody: Full/Part-time employment: Eisai. J. Jing Li: Shareholder/Stockholder/Stock options, Full/Part-time employment:Merck& Co., Inc.; Spouse/Financial dependant, Employment& stocks (immediate family member): Bristol-Myers Squibb. A.B. Siegel: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc.. L. Dubrovsky: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc.. M. Kudo: Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Eisai; Advisory/Consultancy: Ono Pharmaceutical; Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self): Bayer; Research grant/Funding (institution): Otsuka; Research grant/Funding (institution): Taiho Pharmaceutical; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Gilead Sciences; Research grant/Funding (institution): EA Pharma.